Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Low BSA Moderate Plaque Psoriasis With Special Site Involvement
NCT06039189Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2023
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Group 1: Guselkumab with Group 2: Placebo (2 arms). Primary endpoint: Investigator's Global Assessment Score of Cleared (0) or Minimal (1) at 16 weeks. Started Aug 2023; status: completed.
02
Drugs
guselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06039189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06039189.